NEW YORK, July 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=158122&from=4CLASS PERIO ...

SAN DIEGO, July 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049, and pending in the District of New Jersey – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals’ executives with violations of the Securities Exchange Act of 1934. A ...

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rocket-pharmaceuti ...

Core Viewpoint - Rocket Pharmaceuticals is undergoing a strategic reorganization to extend its operational runway and focus on its adeno-associated virus (AAV) cardiovascular platform, which includes several clinical programs [1][2][3]. Group 1: Corporate Reorganization - The restructuring initiative will prioritize resources on clinical programs for Danon disease, PKP2-associated arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy, while also addressing the complete responses to the CRL for KRESLADI [2][3]. - The company plans to reduce its workforce by approximately 30%, which, along with other cost-saving measures, is expected to decrease 12-month operating expenses by nearly 25% [3]. Group 2: Financial Outlook - Rocket anticipates that its existing cash resources will fund operations into the second quarter of 2027 [3]. - Analyst Jason Zemansky from Bank of America downgraded Rocket from Buy to Neutral and reduced the price forecast from $9 to $4, citing weakened investor confidence due to recent failures in the gene therapy sector [5][6]. Group 3: Program Delays and Regulatory Challenges - The company expects delays in the Fanconi Anemia and Pyruvate Kinase Deficiency programs, with regulatory approval for RP-L102 in 2026 now deemed unlikely [4]. - A clinical hold was placed by the FDA on the Phase 2 pivotal trial of RP-A501 for Danon disease, further complicating the company's outlook [4].

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=157787&from=3 CLA ...

Danon disease is a multi-organ lysosomal-associated disorder leading to early death due to heart disorder. SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day. The company's narrative unravele ...

Group 1 - A class action has been filed on behalf of investors who acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025, and May 26, 2025 [1] - The allegations state that Rocket Pharmaceuticals misled investors regarding the viability and efficacy of its RP-A501 drug, particularly concerning the Phase 2 pivotal trial for Danon disease [2] - Following the announcement of a Serious Adverse Event (SAE) related to the trial, Rocket's stock price dropped significantly from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025 [3] Group 2 - The complaint highlights that the company created a false impression of having reliable information about the trial's timeline and safety, which was contradicted by the reality of the situation [2] - The FDA placed the trial on hold due to the introduction of a novel immunomodulatory agent, which was part of an amended protocol that led to a patient's death [2] - Shareholders interested in participating in the class action can contact Robbins LLP, with the option to serve as lead plaintiff or remain an absent class member [4]

SAN DIEGO, July 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 and pending in the District of New Jersey – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934. A subsequently fil ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm or visiting their website [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by August 11, 2025, acting on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for the number of securities class action settlements since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Rocket Pharmaceuticals made misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing serious adverse events, including participant deaths [5]. - It is claimed that these misleading statements led to artificially inflated prices for Rocket Pharmaceuticals securities, resulting in investor damages when the true information became public [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].